MA-PSG
PSG, a leading growth equity firm partnering with lower middle-market software and technology-enabled service companies, today announced that it closed PSG Europe, the firm’s debut Europe-focused fund, with €1.25 billion in limited third-party partner commitments.
The fund, which was oversubscribed, received commitments from existing and new PSG investors, including state pension funds, sovereign wealth funds, family offices and high net worth individuals. The final close of PSG Europe brings PSG’s aggregate capital commitments across the U.S. and Europe to more than $5 billion.
The London-based PSG Europe team consists of 22 investment professionals advising on fund investments in European growth-stage and lower middle-market software and B2B services companies. PSG’s European investment strategy mirrors the firm’s buy and build strategy in the U.S., which has a track record of partnering with management teams to scale businesses through organic and inorganic growth.
“The final close of PSG Europe represents a significant milestone for PSG and firmly establishes our firm as one of Europe’s leading growth equity investors,” said Mark Hastings, Chief Executive Officer of PSG. “We’ve carefully built an exceptional investment team with deep industry expertise to capitalise on the opportunity we see across Europe.”
Peter Wilde, Chairman of PSG, added, “We are thrilled that our inaugural European fund has been met with such strong demand from a high-calibre and diversified group of limited partners. We are grateful for the support the fund has received from both new and returning investors, as it is a testament to the strength of the PSG platform and our investment approach.”
Dany Rammal, Managing Director and Head of the PSG Europe team, said, “The highly fragmented European market presents a significant opportunity for a firm like ours. The strength of our deal sourcing and operational capabilities mean we are well positioned to partner with founders and entrepreneurs to help them grow their businesses into leading pan-European software champions.”
To date, PSG Europe has made seven platform investments in Europe with the acquisitions of Hornetsecurity, Imaweb, MAPAL Group, Nomentia, Signaturit Solutions, SKEEPERS and Sympa, as well as 12 closed add-on acquisitions. Today, PSG’s European portfolio consists of companies with operations across 14 countries, enabling the acceleration of digital software solution adoption across large sectors of the economy.
Notes to Editors
PSG
PSG is a growth equity firm that partners with lower middle-market software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 65 companies and facilitated over 275 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG’s team operates out of offices in Boston, Kansas City and London. To learn more about PSG, visit www.psgequity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005476/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
TOURISE Reframes Tourism Sector as Global Powerhouse on a Path to $16 Trillion During Davos24.1.2026 00:22:00 CET | Press release
TOURISE advanced tourism’s role as a vital sector connecting industries, economies, and regions to address shared global challenges at the World Economic Forum Annual Meeting in Davos. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123950180/en/ His Excellency Ahmed Al‑Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE, convenes executives from Trip.com, Visa, TikTok, PayPal, Salesforce, Forbes, Avolta, ByteDance, and more at Davos 2026 Often overlooked as a siloed industry, TOURISE pressed the importance of tourism being recognized as a strategic sector, contributing one in every $10 to global GDP and uplifting every industry it touches. His Excellency Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE said alliances and collaboration across sectors will see tourism continue to rise. “Tourism is more than a lifestyle sector, it functions as a strategic economic system. TOURISE
Zycus Named a Leader in the 2026 Gartner® Magic Quadrant™ for Source-to-Pay Suites23.1.2026 20:00:00 CET | Press release
This acknowledgment reflects Zycus’ momentum in Agentic AI, comprehensive S2P suite, brand trust and customer outcomes. Zycus, a global provider in Source-to-Pay (S2P) technology, today announced that it has been recognized as a Leaderin the 2026 Gartner® Magic Quadrant™ for Source-to-Pay Suites. We believe the report points to Zycus’ continued investment in Merlin Intake to streamline user experience and Agentic AI to support workflows such as tail-spend management via autonomous negotiation. This aligns with Zycus’ “Intake to Outcomes” (I2O) belief: simplify how work enters procurement, orchestrate execution with Agentic AI, and deliver outcomes with the right governance and control. “Being recognized as a Leader in the Gartner Magic Quadrant for Source-to-Pay Suites reflects our long-term commitment to innovation, customer outcomes, and responsible AI,” said Aatish Dedhia, Founder & CEO of Zycus. “Merlin Agentic AI is designed to move beyond task automation towards end-to-end outcom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom